Release Date: March 17, 2025
Expiration Date: March 17, 2026
Activity Overview
Care of patients with chronic lymphocytic leukemia (CLL), the most common hematologic leukemia among adults worldwide, has rapidly evolved away from chemoimmunotherapy to therapy that disrupts B-cell receptor signaling, including inhibitors of Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2). Clinical trials continue to optimize these treatments in order to maximize efficacy, minimize toxicity, and address areas of unmet need.
This webcast is designed to rapidly disseminate new clinically relevant data with appropriate context. Expert faculty focus on best practices and active areas of debate across the disease continuum.
This educational activity is an archive of the live virtual symposium held on February 20, 2025.
Target Audience
This educational activity is directed toward medical oncologists, hematologists/oncologists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment of CLL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess the role of risk stratification, measurable residual disease (MRD) assessment, and resistance mechanisms in treatment selection and personalization for patients with CLL across multiple therapy lines.
- Analyze trial results from studies that evaluated BCL-2 inhibitor–based strategies in patients with CLL across all therapy lines.
- Devise effective strategies to monitor and mitigate treatment-related toxicities in patients with CLL.
Jennifer R. Brown, MD, PhD
Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Harvard Medical School
Director and Institute Physician, CLL Center
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Grant/Research Support Paid to Institution: BeiGene, iOnctura, Loxo Oncology/Lilly, Gilead, MEI Pharma, TG Therapeutics; Consultant: AbbVie, Acerta Pharma/AstraZeneca, Alloplex Biotherapeutics, BeiGene, Bristol Myers Squibb, Galapagos NV, Genentech/Roche, Grifols Worldwide Operations, Loxo Oncology/Lilly, Magnet Biomedicine, Pharmacyclics, EcoR1, InnoCare Pharma, Kite Pharma, Merck; Royalties: UpToDate; Data Safety Monitoring Board Service: Grifols Therapeutics.
Alexey V. Danilov, MD, PhD
Marianne and Gerhard Pinkus Professor in Early Clinical Therapeutics
Director, Early Phase Therapeutics Program for the Systems Clinical Trials Office
Co-Director, Toni Stephenson Lymphoma Center
Professor, Department of Hematology and Hematopoietic Cell Transplantation
City of Hope
Duarte, CA
Disclosures: Grant/Research Support: AbbVie, AstraZeneca, Bayer Oncology, BeiGene, Bristol Meyers Squibb, Genmab, Incyte, Lilly Oncology, Merck, MEI Pharma, Nurix, TG Therapeutics; Consultant: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genmab, Janssen, Lilly Oncology, MEI Pharma, Merck, Nurix, Regeneron, Roche.
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber Harvard Cancer Center
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Grant/Research Support: Ascentage Pharma, MEI Pharma, Novartis; Consultant: AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lilly, Galapagos NV, Genentech, Genmab, Janssen, Merck, MEI Pharma, Nuvalent, Secura Bio, Takeda, TG Therapeutics; Royalties: UpToDate.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here